...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Prescrire international >blinatumomab (BLINCYTO°) in adults with acute lymphoblastic leukaemia in remission and residual leukaemic cells
【24h】

blinatumomab (BLINCYTO°) in adults with acute lymphoblastic leukaemia in remission and residual leukaemic cells

机译：Blinatumomab（Brincyto°）在缓解和残留睫毛细胞中急性淋巴细胞白血病的成人

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Residual leukaemic cells are frequently cleared after a cycle of blinatumomab, but there is no proven correlation between this surrogate endpoint and a reduced risk of relapse or longer survival. In addition, its adverse effects are often serious, possibly including higher mortality when blinatumomab is used before allogeneic transplantation. The treatment for acute lymphoblastic leukaemia in adults consists of several successive chemotherapy regimens: induction, consolidation, intensification and maintenance. Most patients achieve remission after such treatment. But in about half of them, the disease subsequently relapses. Allogeneic haemopoietic stem cell transplantation is sometimes considered, but it is not always feasible (1). Relapse is thought to be due to the persistence of a very small number of leukaemic cells. This is referred to as minimal residual disease. The lowest proportion of leukaemic cells detectable depends in particular on the technique used, the tissue analysed (blood or bone marrow), and the time elapsed between the end of treatment and testing. The term "minimal residual disease" is generally applied when malignant cells are found using a laboratory test capable of detecting one or more malignant cells per 10 000 normal cells (i.e. a sensitivity of 0.01 %). Although the persistence of leukaemic cells is associated with a higher risk of relapse in patients in remission, not all patients with persistent leukaemic cells relapse, and some patients relapse despite previously having no detectable leukaemic cells (2,3).
机译：在一个周期的blinatumomab治疗后，残留的白血病细胞通常会被清除，但这一替代终点与复发风险降低或存活时间延长之间没有被证实的相关性。此外，其副作用往往很严重，可能包括在同种异体移植前使用布利那单抗时死亡率更高。成人急性淋巴细胞白血病的治疗包括几个连续的化疗方案：诱导、巩固、强化和维持。大多数患者在接受此类治疗后病情缓解。但在其中大约一半人中，这种疾病随后复发。异基因造血干细胞移植有时被认为是可行的，但并不总是可行的（1）。复发被认为是由于极少数白血病细胞的持续存在。这被称为微小残留病。可检测到的白血病细胞的最低比例尤其取决于所使用的技术、所分析的组织（血液或骨髓）以及治疗结束与检测之间经过的时间。“最小残留病”一词通常适用于通过实验室检测发现恶性细胞，该检测能够检测每10000个正常细胞中的一个或多个恶性细胞（即灵敏度为0.01%）。尽管白血病细胞的持续存在与缓解期患者的复发风险较高有关，但并非所有持续性白血病细胞的患者都会复发，有些患者即使之前没有检测到白血病细胞也会复发（2,3）。

著录项

  • 来源
    《Prescrire international》 |2021年第223期|共2页
  • 作者

  • 作者单位
  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药学;
  • 关键词

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号